Mesoblast Stock Rises On Strong Year‑Over‑Year Growth In Ryoncil Sales

Benzinga_recent_news01-10

Mesoblast Ltd (NASDAQ:MESO) shares are trading higher on Friday after the company reported strong year‑over‑year growth in December quarter sales of its flagship therapy, Ryoncil. Mesoblast stock is ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2602303321?lang=en_US&edition=fundamental","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/01/09/Injecting-Injection-Vaccine-Vaccination-.jpeg?optimize=medium&dpr=2&auto=webp&width=240","is_english":true,"pubTime":"2026-01-10 01:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2602303321","market":"hk","top_or_hot":-1,"title":"Mesoblast Stock Rises On Strong Year‑Over‑Year Growth In Ryoncil Sales","media":"Benzinga_recent_news","content":"<div>\n<p>Mesoblast Ltd (NASDAQ:MESO) shares are trading higher on Friday after the company reported strong year‑over‑year growth in December quarter sales of its flagship therapy, Ryoncil.\nMesoblast stock is ...</p>\n\n<a href=\"https://www.benzinga.com/trading-ideas/movers/26/01/49819234/mesoblast-stock-rises-on-strong-year%e2%80%91over%e2%80%91year-growth-in-ryoncil-sales\">Source Link</a>\n\n</div>\n","source":"benzinga_recent_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Mesoblast Stock Rises On Strong Year‑Over‑Year Growth In Ryoncil Sales</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMesoblast Stock Rises On Strong Year‑Over‑Year Growth In Ryoncil Sales\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-10 01:34 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/trading-ideas/movers/26/01/49819234/mesoblast-stock-rises-on-strong-year%e2%80%91over%e2%80%91year-growth-in-ryoncil-sales><strong>Benzinga_recent_news</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Mesoblast Ltd (NASDAQ:MESO) shares are trading higher on Friday after the company reported strong year‑over‑year growth in December quarter sales of its flagship therapy, Ryoncil.\nMesoblast stock is ...</p>\n\n<a href=\"https://www.benzinga.com/trading-ideas/movers/26/01/49819234/mesoblast-stock-rises-on-strong-year%e2%80%91over%e2%80%91year-growth-in-ryoncil-sales\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MESO","symbol_name":"Mesoblast Limited","start_time":0,"source_url":"https://www.benzinga.com/trading-ideas/movers/26/01/49819234/mesoblast-stock-rises-on-strong-year%e2%80%91over%e2%80%91year-growth-in-ryoncil-sales","article_id":"2602303321","we_media_id":null,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/01/09/Injecting-Injection-Vaccine-Vaccination-.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/trading-ideas/movers/26/01/49819234/mesoblast-stock-rises-on-strong-year%e2%80%91over%e2%80%91year-growth-in-ryoncil-sales","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2602303321","pubTimestamp":1767980040,"columns":[],"sourceInfo":{"source_id":"benzinga_recent_news","name":"Benzinga"},"weMediaInfo":null,"summary":"Mesoblast reported strong year‑over‑year growth in December quarter sales of its flagship therapy, Ryoncil.","collect":0,"end_time":0,"defaultTopTitle":"benzinga.com","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"MESO":"Mesoblast Limited"},"translate_title":"Ryoncil销售额同比强劲增长，Mesoblast股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MESO":1.5},"content_text":"Mesoblast Ltd (NASDAQ:MESO) shares are trading higher on Friday after the company reported strong year‑over‑year growth in December quarter sales of its flagship therapy, Ryoncil.\nMesoblast stock is approaching key resistance levels. Why are MESO shares at highs?\nWhat Happened: Mesoblast posted $35.1 million in gross revenue from Ryoncil (remestemcel‑L‑rknd) for the quarter ending Dec. 31, 2025, representing a 60% jump from the previous quarter ending Sept. 30.\nRyoncil is the first mesenchymal stromal cell therapy ever approved by the FDA, and it remains the only FDA‑approved treatment for children under 12 with steroid‑refractory acute graft‑versus‑host disease. The therapy is now moving into a crucial trial as a second‑line option for adults with the same condition, a market roughly three times larger than the pediatric segment.\nThe revenue boost comes as Mesoblast continues to shore up its financial position. The company recently secured a $125 million facility with its largest shareholder, lowering its cost of capital and giving it more flexibility for partnerships and commercialization efforts.\nTechnical Analysis: Mesoblast is currently showing a strong bullish setup, trading well above its key moving averages. The stock is positioned 11.2% above its 20-day SMA, 21.7% above its 50-day SMA and an impressive 44.4% above its 200-day SMA, indicating solid upward momentum.\nThe RSI is currently at 64.96, which is in neutral territory but approaching overbought levels. This suggests that while the stock has momentum, traders should be cautious as it nears the overbought threshold, which could lead to a pullback.\nMACD is below its signal line, indicating bearish pressure in the short term. This could suggest that the recent upward momentum might be losing steam, and traders should watch for any changes in this indicator for potential trend shifts.\nKey support is at $17.50, and if this level is tested, it could signal a potential reversal or trend change. Without a defined resistance level, the stock may continue to push higher, but a breach of support could lead to a more significant decline.\nThe golden cross in August, where the 50-day SMA crossed above the 200-day SMA, marked a significant shift in trend strength. This crossover typically signals a longer-term bullish trend, which traders should consider when evaluating the stock’s performance.\nOver the past 12 months, MESO has gained 23.20%, reflecting a strong longer-term trend. This performance highlights the stock’s recovery and potential for continued growth, especially given its current positioning near the 52-week high.\nMESO Price Action: Mesoblast shares were up 5.23% at $20.91 at the time of publication on Friday. The stock is trading near its 52-week high of $21.00, according to Benzinga Pro.\nImage: Pedro7merino/Shutterstock","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2602303321","isCrawlerRequest":true}